# Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)

> **NCT00844805** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 158 (actual)

## Conditions studied

- Ankylosing Spondylitis
- Axial Spondyloarthritis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Placebo
- **DRUG:** Naproxen

## Key facts

- **NCT ID:** NCT00844805
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2011-04
- **Final completion:** 2011-09
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00844805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00844805, "Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00844805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*